{
    "Symbol": "AUTL",
    "AssetType": "Common Stock",
    "Name": "Autolus Therapeutics Ltd",
    "Description": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.",
    "CIK": "1730463",
    "Exchange": "NASDAQ",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)",
    "Address": "FOREST HOUSE, 58 WOOD LANE, WHITE CITY, LONDON, GB",
    "OfficialSite": "https://www.autolus.com",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2024-12-31",
    "MarketCapitalization": "375242000",
    "EBITDA": "-233072992",
    "PERatio": "None",
    "PEGRatio": "None",
    "BookValue": "1.606",
    "DividendPerShare": "None",
    "DividendYield": "None",
    "EPS": "-0.86",
    "RevenuePerShareTTM": "0.04",
    "ProfitMargin": "0",
    "OperatingMarginTTM": "-2616",
    "ReturnOnAssetsTTM": "-0.26",
    "ReturnOnEquityTTM": "-0.819",
    "RevenueTTM": "10120000",
    "GrossProfitTTM": "-130900000",
    "DilutedEPSTTM": "-0.86",
    "QuarterlyEarningsGrowthYOY": "0",
    "QuarterlyRevenueGrowthYOY": "6.81",
    "AnalystTargetPrice": "10.1",
    "AnalystRatingStrongBuy": "2",
    "AnalystRatingBuy": "8",
    "AnalystRatingHold": "0",
    "AnalystRatingSell": "0",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "-",
    "ForwardPE": "-",
    "PriceToSalesRatioTTM": "43.94",
    "PriceToBookRatio": "1.034",
    "EVToRevenue": "34.98",
    "EVToEBITDA": "0.0326",
    "Beta": "2.064",
    "52WeekHigh": "5.84",
    "52WeekLow": "1.392",
    "50DayMovingAverage": "1.951",
    "200DayMovingAverage": "3.2",
    "SharesOutstanding": "266129000",
    "DividendDate": "None",
    "ExDividendDate": "None"
}